Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | B2M over exp |
Therapy | Bortezomib |
Indication/Tumor Type | multiple myeloma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
B2M over exp | multiple myeloma | predicted - sensitive | Bortezomib | Preclinical | Actionable | In a preclinical study, B2M over expressing multiple myeloma cells resistant to Velcade (bortezomib) demonstrated increased apoptotic activity when treated with a combination of Velcade (bortezomib) and anti-beta 2 microglobulin monoclonal antibodies (PMID: 25895124). | 25895124 |
PubMed Id | Reference Title | Details |
---|---|---|
(25895124) | Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. | Full reference... |